Patent Portfolio

ViaCyte’s patent portfolio includes hundreds of issued patents worldwide, and patent terms in the space extend for the next two decades or more. Patents have been issued in the United States and many countries around the world, including Australia, Belgium, Canada, China, Denmark, France, Germany, Hong Kong, Iceland, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Republic of Korea, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, and the United Kingdom.

ViaCyte’s patent portfolio covers many of the intermediary cell types generated when human pluripotent stem cells progress along the differentiation pathway to pancreatic cells. ViaCyte has proprietary protocols for generating pancreatic progenitors and pancreatic endocrine cells at various stages of differentiation.

• Culturing and expanding human pluripotent stem cells (e.g., human embryonic stem cells and induced pluripotent stem cells) and differentiating them to pancreatic progenitor and later stage endocrine precursor and endocrine cells including definitive endoderm, mesendoderm, and primitive foregut intermediate cell types
• Cell suspension and scale-up culture methods
• Pluripotent stem cell defined media
• Cryopreservation of pancreatic type cells
• Immune-evasive gene-edited pluripotent stem cells and cells derived from them
• Encapsulation of pancreatic cells
• Large-capacity cell encapsulation delivery device
• Directly vascularized delivery device
• Various tools and devices for the combination product including cell loading, packaging, and storage